{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:56:07Z","timestamp":1790657767449,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"BridgeBio Pharma Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03664-7","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:28:21Z","timestamp":1784104101000},"page":"4327-4343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vutrisiran Health Care Resource Utilization, Costs, Discontinuation, and Mortality: A Real-World Claims Analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3546-0758","authenticated-orcid":false,"given":"Nicole K.","family":"Bart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-0248","authenticated-orcid":false,"given":"Daniel P.","family":"Judge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Udall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Hennum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shradha","family":"Sanghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3590-3274","authenticated-orcid":false,"given":"Richard","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"22","key":"3664_CR1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"3664_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14134785","volume":"14","author":"C Tschope","year":"2025","unstructured":"Tschope C, Elsanhoury A, Kristen AV. Transthyretin amyloid cardiomyopathy-2025 update: current diagnostic approaches and emerging therapeutic options. J Clin Med. 2025;14(13):4785.","journal-title":"J Clin Med"},{"issue":"4","key":"3664_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/13506129.2024.2405948","volume":"31","author":"JN Buxbaum","year":"2024","unstructured":"Buxbaum JN, Eisenberg DS, Fandrich M, et al. Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2024;31(4):249\u201356.","journal-title":"Amyloid"},{"issue":"2","key":"3664_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40119-021-00222-w","volume":"10","author":"H Koike","year":"2021","unstructured":"Koike H, Okumura T, Murohara T, Katsuno M. Multidisciplinary approaches for transthyretin amyloidosis. Cardiol Ther. 2021;10(2):289\u2013311.","journal-title":"Cardiol Ther"},{"issue":"1","key":"3664_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40120-020-00183-7","volume":"9","author":"A Gonzalez-Duarte","year":"2020","unstructured":"Gonzalez-Duarte A, Conceicao I, Amass L, Botteman MF, Carter JA, Stewart M. Impact of non-cardiac clinicopathologic characteristics on survival in transthyretin amyloid polyneuropathy. Neurol Ther. 2020;9(1):135\u201349.","journal-title":"Neurol Ther"},{"issue":"4","key":"3664_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40119-025-00421-9","volume":"14","author":"J Wixner","year":"2025","unstructured":"Wixner J, Dispenzieri A, Amass L, et al. Survival in a contemporary, real-world cohort of patients with mixed-phenotype transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from THAOS. Cardiol Ther. 2025;14(4):583\u201399.","journal-title":"Cardiol Ther"},{"key":"3664_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2026.04.004","author":"A Masri","year":"2026","unstructured":"Masri A, Wright R, Betts M, et al. Evolution of patient characteristics and outcomes in ATTR-CM clinical trials: a systematic review. Prog Cardiovasc Dis. 2026. https:\/\/doi.org\/10.1016\/j.pcad.2026.04.004.","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"3664_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/13506129.2025.2462541","volume":"32","author":"S Rebello","year":"2025","unstructured":"Rebello S, Hsu K, Nativi-Nicolau J, et al. Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium\u2019s treatment affordability patient and caregiver survey. Amyloid. 2025;32(2):161\u201370.","journal-title":"Amyloid"},{"issue":"suppl 1","key":"3664_CR9","volume":"150","author":"J Grodin","year":"2024","unstructured":"Grodin J, Masri A, Wright R, et al. Abstract 4142045: costs and healthcare resource utilization in transthyretin amyloid cardiomyopathy exceeds that of non-amyloid heart failure. Circulation. 2024;150(suppl 1):A4142045.","journal-title":"Circulation"},{"issue":"5","key":"3664_CR10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/14737167.2021.1900738","volume":"21","author":"L Galan","year":"2021","unstructured":"Galan L, Gonzalez-Moreno J, Mart\u00ednez-Sesmero JM, et al. Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain. Expert Rev Pharmacoecon Outcomes Res. 2021;21(5):967\u201373.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6 suppl 1","key":"3664_CR11","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.1016\/j.jval.2025.04.972","volume":"28","author":"G Chen","year":"2025","unstructured":"Chen G, Rikner K, Grandy S, et al. HSD76 a real-world study on healthcare resource utilisation and patient care for people with transthyretin amyloid polyneuropathy. Value Health. 2025;28(6 suppl 1):S239\u201340.","journal-title":"Value Health"},{"issue":"4","key":"3664_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/14737167.2025.2450310","volume":"25","author":"S Calabria","year":"2025","unstructured":"Calabria S, Ronconi G, Dondi L, et al. A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy. Expert Rev Pharmacoecon Outcomes Res. 2025;25(4):535\u201342.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"3664_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/14737167.2025.2527269","volume":"25","author":"F Mart\u00ednez Valle","year":"2025","unstructured":"Mart\u00ednez Valle F, Gal\u00e1n D\u00e1vila L, Buades Rein\u00e9s J, et al. Economic and healthcare resource utilization for hereditary transthyretin amyloidosis with polyneuropathy in Spain: real-world insights from early-stage patients and mutation carriers. Expert Rev Pharmacoecon Outcomes Res. 2025;25(7):1115\u201323.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"3664_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/13506129.2019.1701429","volume":"27","author":"M In\u00eas","year":"2020","unstructured":"In\u00eas M, Coelho T, Concei\u00e7\u00e3o I, Landeiro F, de Carvalho M, Costa J. Societal costs and burden of hereditary transthyretin amyloidosis polyneuropathy. Amyloid. 2020;27(2):89\u201396.","journal-title":"Amyloid"},{"key":"3664_CR15","unstructured":"Amvuttra [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; 2025."},{"issue":"3","key":"3664_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40119-025-00424-6","volume":"14","author":"E Margolin","year":"2025","unstructured":"Margolin E, Stern LK, Argiro A, Rosenthal JL, Urey MA, Alexander KM. Current and future treatment landscape of transthyretin amyloid cardiomyopathy. Cardiol Ther. 2025;14(3):385\u2013401.","journal-title":"Cardiol Ther"},{"key":"3664_CR17","unstructured":"Vutrisiran. RED BOOK Online. IBM Micromedex [database online]. Truven Health Analytics\/IBM Watson Health; 2020. https:\/\/www.micromedexsolutions.com\/. Accessed 30 Oct 2025."},{"issue":"1","key":"3664_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, The HELIOS-A Collaborators, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):18\u201326.","journal-title":"Amyloid"},{"issue":"1","key":"3664_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, for the HELIOS-B Trial Investigators, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392(1):33\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"3664_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health"},{"issue":"4","key":"3664_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/HYPERTENSIONAHA.111.171074","volume":"58","author":"HA van Onzenoort","year":"2011","unstructured":"van Onzenoort HA, Menger FE, Neef C, et al. Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension. 2011;58(4):573\u20138.","journal-title":"Hypertension"},{"key":"3664_CR22","unstructured":"Business of. Optum claims data: clinformatics data mart; 2026. https:\/\/ohdsi.github.io\/CommonDataModel\/. Accessed 27 Apr 2026."},{"key":"3664_CR23","unstructured":"Health K. Komodo healthcare map; 2026. https:\/\/www.komodohealth.com\/product\/healthcare-map\/. Accessed 27 Apr 2026."},{"key":"3664_CR24","unstructured":"Santo L, Schappert SM, Ward BW. Emergency department visits by adults age 65 and older with alzheimer disease: United States, 2020\u20132022. NCHS Data Brief, no 510. Hyattsville, MD: National Center for Health Statistics. 2024."},{"issue":"8","key":"3664_CR25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jchf.2022.05.006","volume":"10","author":"R Bhatnagar","year":"2022","unstructured":"Bhatnagar R, Fonarow GC, Heidenreich PA, Ziaeian B. Expenditure on heart failure in the United States: the Medical Expenditure Panel Survey 2009-2018. JACC Heart Fail. 2022;10(8):571\u201380.","journal-title":"JACC Heart Fail"},{"issue":"3","key":"3664_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cardfail.2021.12.017","volume":"28","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Fonarow GC, Opsha Y, et al. Economic issues in heart failure in the United States. J Card Fail. 2022;28(3):453\u201366.","journal-title":"J Card Fail"},{"key":"3664_CR27","unstructured":"Leqvio [package insert]. East hanover, NJ: Novartis Pharmaceuticals Corporation; 2025."},{"issue":"4 suppl","key":"3664_CR28","doi-asserted-by":"publisher","first-page":"E515","DOI":"10.1016\/j.jacl.2024.04.045","volume":"18","author":"L Popadic","year":"2024","unstructured":"Popadic L, Ma X, Ali Y, et al. Treatment patterns among early inclisiran vs anti-PCSK9 mAbs users: a retrospective analysis of US claims databases. J Clin Lipidol. 2024;18(4 suppl):E515\u20136.","journal-title":"J Clin Lipidol"},{"issue":"suppl 1","key":"3664_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-137560","volume":"136","author":"KE Sandman","year":"2020","unstructured":"Sandman KE, Bell TJ. Patient-focused benefits of at-home versus in-clinic administration of cancer therapy: new considerations for the COVID-19 era. Blood. 2020;136(suppl 1):35\u20136.","journal-title":"Blood"},{"issue":"11","key":"3664_CR30","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1080\/03007995.2025.2596820","volume":"41","author":"CI Coleman","year":"2025","unstructured":"Coleman CI, Martinez R, Torres SA. Methods of identifying transthyretin amyloid cardiomyopathy in secondary data sources: a systematic review. Curr Med Res Opin. 2025;41(11):2013\u201324.","journal-title":"Curr Med Res Opin"},{"key":"3664_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1638380","volume":"12","author":"RM Witteles","year":"2025","unstructured":"Witteles RM, Chung H, Dai F, et al. Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy. Front Cardiovasc Med. 2025;12:1638380.","journal-title":"Front Cardiovasc Med"},{"key":"3664_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-026-04787-5","author":"EB Tapper","year":"2026","unstructured":"Tapper EB, Ryan T, Lewandowski D, Winer-Jones JP, Bonafede M, Kim Y. Burden of metabolic dysfunction-associated steatohepatitis, with and without metabolic syndrome, obesity, or diabetes. BMC Gastroenterol. 2026;26(1):301.","journal-title":"BMC Gastroenterol"},{"key":"3664_CR33","doi-asserted-by":"crossref","unstructured":"Dauber A, Abuzzahab MJ, Chen JV, et al. Real-world evidence of treatment patterns and costs of turner syndrome and noonan syndrome in the USA. Horm Res Paediatr. 2025. 1\u201319.","DOI":"10.1159\/000550211"},{"key":"3664_CR34","unstructured":"Facts U. Which states spend the most on healthcare? 2026. https:\/\/usafacts.org\/articles\/which-states-spend-the-most-on-healthcare\/. Accessed 27 Apr 2026."}],"updated-by":[{"DOI":"10.1007\/s12325-026-03764-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03664-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03664-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03664-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:14:24Z","timestamp":1790655264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03664-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3664"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03664-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to update in Key Summary Point.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-026-03764-4","URL":"https:\/\/doi.org\/10.1007\/s12325-026-03764-4","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nicole K. Bart received research funding from Pfizer; reports speaking fees from Pfizer; and reports advisory board fees from BridgeBio Pharma, Inc., Bristol Myers Squibb, Novo Nordisk, and Pfizer. Daniel P. Judge reports consultancy fees from Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Attralus, Bayer, BridgeBio Pharma, Inc., Cytokinetics, Lexeo Therapeutics, Novo Nordisk, Rocket Pharmaceuticals, and Tenaya Therapeutics. Margarita Udall is an employee and stockholder of BridgeBio Pharma, Inc.; and stockholder of Pfizer. Liana Hennum is an employee and stockholder of BridgeBio Pharma, Inc. Melissa Allison, Avinash Dash, Shradha Sanghi, and Rakesh Ramesh are employees of Definitive Healthcare, which received financial compensation from BridgeBio Pharma, Inc. for performing research. Richard Wright reports research funding from BridgeBio Pharma, Inc. and Cytokinetics; speaking fees from Alnylam Pharmaceuticals, American Heart Association, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, BridgeBio Pharma, Inc., Lexicon, Lilly, and Novartis; consultancy fees from Alnylam Pharmaceuticals, American College of Cardiology, American Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, BridgeBio Pharma, Inc., Cytokinetics, MyoKardia, Novartis, and Providence Health; advisory board fees from Alnylam Pharmaceuticals, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, BridgeBio Pharma, Inc., Cytokinetics, and Novartis.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Optum\n                      \u00ae\n                      CDM and Komodo databases comply with the Health Insurance Portability and Accountability Act. Given the anonymized, de-identified nature of the data, patient consent was not possible or required, and institutional review board approval to conduct this study was not necessary. Only aggregate cohort-level results were reported, without identification of any health care providers or healthcare facilities.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}